OBJECTIVES: Minimally invasive surgery is accepted for early-stage lung cancer, but its role in locally advanced disease is controversial, especially using a robotic platform. The aim of this retrospective study was to assess the safety and effectiveness of robot-assisted resection in patients with Stage IIIA non-small-cell lung cancer (NSCLC) or carcinoid tumours in the series as a whole and in different subgroups according to adjuvant treatment.
INTRODUCTION
Minimally invasive video-assisted thoracoscopic surgery (VATS) lung resection is associated with reduced postoperative pain, reduced cytokine responses, quicker resumption of normal activities and better aesthetic and functional outcomes than thoracotomy [1] [2] [3] [4] [5] [6] . Nevertheless, VATS has not been embraced by the majority of thoracic surgeons [7] , probably due to its technical challenges, steep learning curve and difficulties in performing complete mediastinal lymphadenectomy, which is standard for lung cancer surgery [8] [9] , and many thoracic surgeons prefer open thoracotomy for pulmonary lobectomy [7] .
Robot-assisted surgery has several advantages over VATS, including improved 3-dimensional visualization, instruments with more degrees of motion freedom and better ergonomics [10] [11] [12] [13] [14] [15] [16] . These improvements have allowed surgeons who do not perform VATS to find a minimally invasive platform that they can use. In addition, lymph node dissection is easier and likely to be more complete with robot-assisted surgery than with VATS [15, 16] and is, therefore, suitable for lung cancer cases with mediastinal lymph node involvement, which are usually subjected to thoracotomy. Furthermore, since robot-assisted surgery and VATS are associated with quicker recovery than open surgery, cases with N2 disease not given neoadjuvant chemotherapy have a greater probability of initiating full-dose adjuvant chemotherapy within the 6 weeks after surgery considered optimal.
Minimally invasive lung resections are generally indicated for early-stage (Stages I or II) lung cancer [17] , and several groups have reported experience and initial outcomes of robot-assisted lung resection for early disease [11] [12] [13] [14] [15] [16] . To our knowledge, however, only 3 studies have described VATS to treat locally advanced non-small-cell lung cancer (NSCLC) [18] [19] [20] , and another 2 have reported on the use of robotic surgery for locally advanced disease [15, 21] . The aim of this retrospective study was to assess the safety and effectiveness of robot-assisted lung resection in patients with Stage III NSCLC or carcinoid. We were also interested in assessing long-term outcomes in NSCLC patients, particularly those who received induction chemotherapy. The operations were carried out at 7 centres in Europe, North America and Asia Minor.
METHODS
We performed a retrospective analysis of prospectively collected data from 7 centres with experience in performing robot-assisted surgery and whose principal surgeons had all attained proficiency in robotic surgery for lung cancer resection. Eligible cases had NSCLC or carcinoid, with pathological (post-surgical) N2 disease (Stage IIIA) diagnosed either before surgery (clinical N2) or encountered intraoperatively (occult N2) and treated by robotassisted resection with curative intent, before or after chemotherapy or chemoradiation therapy. Patients with clinical N2 but pathological yN0 or yN1 were excluded, as the absence of access to the radiological images made it impossible to confirm preoperative stage. Carcinoid tumours were excluded from the survival analyses. For patients treated from 9 November 2005 to 15 July 2017, information on duration of surgery, extent of lymphadenectomy, perioperative complications according to Clavien-Dindo [22] , conversions to open surgery, mortality, length of hospital stay, local and distant recurrences and overall and disease-specific survival were assessed.
Two surgical techniques were used. Surgeons from 4 centres (Milan, New York, Tampa and Istanbul) used a 3-or 4-arm approach, with a utility incision, no CO 2 insufflation and anteriorto-posterior hilar dissection. The other 3 North American centres used 3-4 arms, CO 2 insufflation, posterior-to-anterior hilar dissection and a specimen extraction incision at the end of the procedure.
Statistical methods
Data are presented for the whole series and by adjuvant treatment group (preoperative, postoperative and none). Categorical data are summarized as numbers and percentages. Continuous data are summarized as means with standard deviations (SDs) or medians and interquartile ranges. Differences between the adjuvant treatment groups were explored using the Kruskal-Wallis nonparametric test for continuous variables or v 2 test for categorical variables. Differences between 2 groups were explored using the Wilcoxon non-parametric test (continuous) or the v 2 test (categorical). Variables with P-value <0.1 were entered into a multivariable logistic regression model, with differences in P-value <0.05 considered significant. Survival was calculated from day of surgery to death or latest contact. Survival curves were constructed by the Kaplan-Meier method. All factors were tested for their influence in survival by the Cox proportional hazards modelling: factors with P-value <0.1 using univariate analysis were entered into a Cox multivariable model. The proportional hazards assumption was evaluated for all factors using Schoenfeld residuals.
RESULTS
A total of 223 patients conformed to our inclusion criteria and were analysed. N2 disease was diagnosed preoperatively in 72 (32%) patients and intraoperatively in 151 (68%) patients. The mean duration of surgery was 194 min (SD 82). Neoadjuvant treatment was given to 34 (15%) patients, adjuvant treatment to 140 (63%) patients and no neoadjuvant/adjuvant treatment to 49 (22%) patients ( Table 1 ). The mean duration of hospital stay was 5.3 days and did not differ (P = 0.64) among the 3 adjuvant treatment groups.
Severe (Clavien-Dindo Grade III-V) postoperative complications occurred in 23 (10.3%) cases, with no difference (P = 0.14) between those who received neoadjuvant chemotherapy or surgery as first treatment. Twenty-two (9.9%) cases were converted to thoracotomy, with no difference between the treatment groups (P = 0.35). Causes of conversion were oncological in 7 (including 3 with unforeseen mediastinal nodal involvement), bleeding in 6, anatomical in 7 (including tight adhesions in 5) and technical in 2 (including 1 intraoperative airway complication). Factors significantly associated with conversion were large tumour size and >2 positive lymph nodes but only using univariable analysis (Table 2) . No factor was significantly associated with conversion using multivariable analysis.
Of the 34 patients given neoadjuvant chemotherapy, 8 also received preoperative radiotherapy. All patients had negative surgical margins. Five (15%) required conversion, and none because of bleeding. None had a blood transfusion. Four (12%) patients had Grade III or IV postoperative complications. The mean postoperative hospital stay was 5 days. None died within 30 or 90 days, although 2 were lost to follow-up at 30 days and 3 at 90 days.
Negative surgical margins were obtained in 185 (98.4%) of the 188 cases with available data. Of the 189 patients not given neoadjuvant therapy, 47 (25%) patients had suspected or proven clinical N2 disease but were intentionally operated on before chemotherapy, whereas 142 (75%) patients had nodal disease discovered only during surgery. Using univariable analysis (Table 3) , no variable was significantly associated with complications. A mean of 15.4 (SD 7.9) lymph nodes was removed, and 4.3 (SD 4.9) of which were positive; a mean of 7.0 (SD 4.1) lymph nodes were removed from Station N1 and a mean of 8.3 (SD 6.1) lymph nodes were removed from Station N2; 203 (91.0% of 223) patients had more than 6 lymph nodes removed.
Overall, 56 (25%) patients had distant relapse, whereas local or lung recurrence occurred in 37 (16.6%) patients: in 6 cases (2 carcinoids) in hilar or mediastinal lymph nodes and in 19 (8.5%) cases, the recurrence was described as in the lung, but it was not possible to distinguish between second primary, metastasis and local relapse from the records.
After a median follow-up of 18 (interquartile range 9-32) months, median survival for the 210 NSCLC patients was 51 months, with 3-year overall survival (OS) estimated at 61.2% (95% confidence interval 51.7-69.4%). OS was similar (log-rank P = 0.134) in the 3 adjuvant treatment groups (Fig. 1) . Large tumour size, the presence of postoperative complications, advanced age and male sex were significantly associated with worse OS in the univariable analyses. Only large tumour size, the presence of postoperative complications and advanced age were associated with worse survival in the multivariable model ( Table 4 ). Figure 2 shows that OS was worse (log rank P = 0.010) in patients with >2 involved lymph nodes when compared with those with < _2 involved nodes, whereas OS did not differ between cases with clinically evident versus occult N2 disease or between cases with and without skip metastases.
DISCUSSION
In this retrospective multicentre study of 223 patients with clinically evident or occult N2 lung cancer who underwent robotassisted lung resection, we found that perioperative outcomes were highly encouraging. Only 2.7% (95% confidence interval 0.99-5.76%) of cases were converted to open surgery due to bleeding. A similar figure (vascular injuries in 2.9% and leading to conversion in 2.2%) was reported for VATS resections of 3076 lung cancer cases (all stages) archived in the European Society of Thoracic Surgeons database [23] . A somewhat lower proportion of bleeding complications (1.7% for both VATS and robotassisted surgery) was reported for major lung resections archived in the US national database [24] . In the same database, the conversion rate did not differ significantly between patients who underwent surgery after neoadjuvant treatment versus those who underwent surgery before adjuvant treatment. In our series, large tumour size and >2 positive lymph nodes were associated with conversion to thoracotomy (univariate analysis only), suggesting that patients with more advanced disease should be informed of the greater risk of conversion to open surgery. However, only 3 of the 151 patients with unforeseen mediastinal nodal invasion required conversion to open surgery. This is an acceptable figure and suggests that unforeseen mediastinal lymph node involvement is not a major cause of conversion in robot-assisted surgery. A large retrospective analysis of lung cancers treated by VATS had suggested unforeseen mediastinal lymphadenopathy as a potential cause of conversion [22] . We also found that estimated 3-year OS (excluding carcinoids) was good at 61.2%. Patients with Stage III NSCLC constitute a heterogeneous group, and outcomes vary considerably. Factors reported to predict better survival include limited mediastinal lymph node disease, good response to induction therapy and the absence of comorbidities [25] . The favourable outcomes in our NSCLC patients are likely to be in part due to the fact that two-thirds had clinically occult nodal involvement, with relatively good prognosis; furthermore, all underwent preoperative PET and a large proportion probably had routine brain imaging.
Only a small proportion (15%) of our series received preoperative chemotherapy, because a large proportion (142/223, 63%) had occult N2 disease, which was only detected intraoperatively. However, a further 47 cases had suspected or proven N2 disease but were intentionally operated on before chemotherapy, in accordance with the treatment policy of one of the participating centres (Moffitt Cancer Center, Tampa, FL, USA). Because our study was retrospective, we did not have reliable data on how many N2 cases had microscopic involvement and how many were truly locally advanced with involvement of nearby structures.
To our knowledge, 3 articles have presented data on the use of VATS to treat locally advanced NSCLC [18] [19] [20] , and 2 articles have described robot-assisted surgery for locally advanced disease [15, 21] . Data on these 5 studies, in comparison with the findings of this study, are summarized in Table 5 . The study by Petersen et al. [18] reported on the feasibility and safety of VATS lobectomy in 12 patients who received preoperative chemotherapy and/or radiotherapy for locally advanced disease. One case was converted to open surgery. The authors concluded that VATS was safe, that outcomes were relatively good and that length of hospital stay (2 days) was shorter than for the 85 thoracotomy cases. However, the small size of the VATS group and smaller average tumour size in this group were study limitations.
Nakanishi et al. [19] retrospectively reviewed data on 76 patients with Stage II or Stage III NSCLC treated by VATS. Induction treatment was given to 12 patients. Mean duration of surgery was 327 min, but 36% of cases underwent resection of adjacent structures. A mean of 16 lymph nodes was removed. In-hospital mortality was 2.6%. In the 33 cases with Stage III disease, 3-year survival was 36.2%.
Hennon et al. [20] reported on 16 Stage III patients treated using induction chemotherapy and VATS. Perioperative outcomes were good, and 3-year OS was around 62%, which is similar to the OS in our series. The 2016 article by Park et al. [21] retrospectively assessed 428 patients with locally advanced NSCLC, with 397 treated by thoracotomy, 17 by robot-assisted surgery and 14 by VATS. Oncological outcomes were similar in the open and minimally invasive groups, but the latter had a significantly shorter length of hospital stay.
The 2011 article by Dylewski et al. [15] reported on optimal perioperative outcomes with robot-assisted surgery to treatment 15 patients with locally advanced NSCLC pretreated using chemotherapy and/or chemoradiation therapy.
Large central tumours, multistation lymph node involvement and previous irradiation render the surgical management of locally advanced lung cancers highly challenging; as a result, outcomes are variable. Nevertheless, in selected patients with Stage III NSCLC and good prognostic factors, minimally invasive surgery has been reported as safe and effective [19] . Our experience with the N2 cases of this series, particularly the 34 patients who received preoperative chemotherapy, further supports this conclusion. Among these 34 patients, 8 of whom also received preoperative radiotherapy, an R0 resection was achieved in all, none had a blood transfusion or required conversion for bleeding and only 12% had Grade III-IV postoperative complications. However, we do not know the proportion of N2 patients (treated at the same time) who received preoperative chemotherapy plus radiotherapy and proceeded directly to open surgery, emphasizing the highly selected nature of our series. It should also be noted that we have excluded cN2 patients who were downstaged to ypN1 or ypN0, so as to study a homogenous cohort of pN2 cases: ypN1 and ypN0 cases may have had better outcomes.
Limitations
The main limitations of our study arise from its retrospective nature. Thus, the proportion of R0 resections carried out according to the International Association for the Study of Lung Cancer (IASLC) specifications [26] could not be reconstructed because data on lymph nodes removed in fragments, the highest station was involved and the presence/absence of extracapsular invasion in positive nodes were not available. We were also unable to assess the proportion of patients with NSCLC in the left upper lobe in whom Station 4L was removed. Nevertheless, in 97% of our series, at least 6 lymph nodes were removed in accordance with the European Society of Thoracic Surgeons (ESTS)/IASLC guidelines, although we were unable to ascertain whether at least 3 nodes were removed from mediastinal stations. This contrasts with a recent article on nodal staging during surgical resection of NSCLC [27] in which at least 6 lymph nodes were removed in only 53% of cases.
The strengths of our study are that it investigated a consecutive series of patients with sufficiently long follow-up (median 18 months) with all patients being staged preoperatively with PET and all receiving complete thoracic node dissection.
To our knowledge, this is the largest series of patients with pN2 disease treated robotically although some patients are also reported on in a recent article on long-term survival in NSCLC that places considerable emphasis on N2 cases [27] . The low conversion rate for bleeding, low 30-day mortality and 90-day mortality (zero for neoadjuvant cases) and good 3-year OS suggest that the robotic approach to locally advanced lung cancer is safe and effective.
